Trastuzumab deruxtecan (T-DXd), an anti-HER2 monoclonal antibody conjugated to a topoisomerase I inhibitor via a tetrapeptide-based cleavable linker, has gained approval for metastatic HER2-positive BC [23]. The gene discussed is ERBB2; the disease is breast cancer.